For Immediate Release
New Drug Target for Inflammatory Disease Is All the RAGE
New Rochelle, NY, December 21, 2016--Researchers have shown that Receptor for Advanced Glycation End Products (RAGE) helps to regulate a key signaling pathway known to promote both acute and chronic inflammation. The development of therapeutic drugs targeted to RAGE could be used to treat a range of inflammatory diseases such as asthma, infection, atherosclerosis, and arthritis, as described in an article in DNA and Cell Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DNA and Cell Biology website until January 18, 2017.
In "Receptor for Advanced Glycation End Products (RAGE) Regulates Leukotriene B4 Receptor 1 Signaling," authors Takako Ichiki Tomoaki Koga, and Takehiko Yokomizo, Juntendo University School of Medicine, Tokyo, and Kumamoto University, Kumamoto, Japan, report how they observed that RAGE binds to the leukotriene B4 receptor 1 (BLT1) receptor. This interaction between RAGE and BLT1 modifies LTB4-BLT1 signaling, which modulates the inflammatory response through its effects on cell migration.
"RAGE is an alarmin, a molecule that alerts the host of potential risks and challenges. It is induced in inflammatory conditions or diseases and promotes more inflammation," says Carol Shoshkes Reiss, PhD, Editor-in-Chief, of DNA and Cell Biology and Professor, Departments of Biology and Neural Science, and Global Public Health at New York University, NY. "By developing new drugs to block the interaction of RAGE with its receptor, in the future, there may be treatments of some aspects of these diseases."
About the Journal
DNA and Cell Biology is the trusted source for authoritative, peer-reviewed reporting on the latest research in the field of molecular biology. By combining mechanistic and clinical studies from multiple systems in a single journal, DNA and Cell Biology facilitates communication among biological sub-disciplines. Coverage includes gene structure, function, and regulation, molecular medicine, cellular organelles, protein biosynthesis and degradation, and cell-autonomous inflammation and host cell response to infection. Complete tables of content and a sample issue may be viewed on the DNA and Cell Biology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Antioxidants and Redox Signaling, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.